Strong Earnings Growth
Adjusted earnings per share increased by 18% over the prior year quarter, exceeding the high end of guidance range with $1.66 per share.
Robust Pharma Segment Performance
Pharma segment showed strong core sales growth with Prescription increasing by 8%, Injectables by 9%, and Active Materials Science Solutions by 11%.
Successful Mod3 Pharma Acquisition
Acquisition of Mod3 Pharma's clinical trial manufacturing capabilities expands Aptar Pharma services and strengthens its position in early-stage development.
Recognition and Awards
Aptar named one of Time Magazine's World's Most Sustainable Companies for the second consecutive year and added to CDP's Supplier Engagement Assessment A List.
Closure Segment Growth
Core sales in the Closures segment increased by 7%, driven by strong demand in food and beverage markets.
Improved EBITDA Margin
Consolidated adjusted EBITDA margins expanded by 140 basis points to 22.6% compared to 21.2% in the prior year.